BPG is committed to discovery and dissemination of knowledge
Articles in Press
12/25/2025 9:42:13 AM | Browse: 0 | Download: 0
Publication Name World Journal of Gastroenterology
Manuscript ID 114544
Country China
Category Gastroenterology & Hepatology
Manuscript Type Basic Study
Article Title Lianhe Xiaozhi ointment ameliorates metabolic dysfunction-associated steatotic liver disease via peroxisome proliferator-activated receptor alpha pathway activation
Manuscript Source Unsolicited Manuscript
All Author List Li-Juan Nie, Gao-Xiang Wang, Xin-Yi Yang, Jing Sun, Yu-Tian Cao, Yan Lou, Yi-Fan Lu, Jiang-Yi Yu and Xi-Qiao Zhou
Funding Agency and Grant Number
Funding Agency Grant Number
National Natural Science Foundation of China No. 82474318
Jiangsu Administration of Traditional Chinese Medicine No. QN202411
Special Fund for Training Outstanding Young Doctors in the Second Session of Jiangsu Province Hospital of Chinese Medicine No. 2024QB002
Corresponding Author Xi-Qiao Zhou, Director, PhD, Professor, Department of Endocrinology, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, No. 155 Hanzhong Road, Qinhuai District, Nanjing 210029, Jiangsu Province, China. zhouxiqiao@njucm.edu.cn
Key Words Metabolic dysfunction-associated steatotic liver disease; Traditional Chinese medicine; Peroxisome proliferator-activated receptor alpha; Inflammation; Network pharmacology
Core Tip Lianhe Xiaozhi ointment effectively alleviates metabolic dysfunction-associated steatotic liver disease by improving glucolipid metabolism, reducing liver injury and inflammation, and modulating gut microbiota. Its therapeutic effect is primarily mediated via activation of peroxisome proliferator-activated receptor alpha signaling. These insights provide a theoretical foundation for the clinical application of Lianhe Xiaozhi ointment.
Citation Nie LJ, Wang GX, Yang XY, Sun J, Cao YT, Lou Y, Lu YF, Yu JY, Zhou XQ. Lianhe Xiaozhi ointment ameliorates metabolic dysfunction-associated steatotic liver disease via peroxisome proliferator-activated receptor alpha pathway activation. World J Gastroenterol 2025; In press
Received
2025-09-30 03:07
Peer-Review Started
2025-09-30 03:07
First Decision by Editorial Office Director
2025-10-27 09:52
Return for Revision
2025-10-27 09:52
Revised
2025-11-06 04:02
Publication Fee Transferred
2025-11-10 09:05
Second Decision by Editor
2025-12-25 02:35
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director
2025-12-25 09:42
Articles in Press
2025-12-25 09:42
Edit the Manuscript by Language Editor
Typeset the Manuscript
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com